Serial assessment of levels of autoantibodies has been proposed as being clinically useful in certain systemic autoimmune diseases. In particular, attention has been given to anti-dsDNA antibodies in systemic lupus erythematosus (SLE) and ANCA in the ANCA-associated vasculitides (AAV). Much controversy exists, however, concerning the value of serial testing in these diseases. We here review the various tests available for quantitation of anti-dsDNA and ANCA, and their capacity to detect changes in autoantibody levels that are associated with changes in clinical disease activity of the respective diseases. It is concluded that changes in anti-dsDNA as measured by the Farr assay and changes in ANCA as assessed by ELISA have predictive value for the occurrence of disease relapses, although this relationship is far from absolute. Consequently, treatment based on changes in levels of the respective autoantibodies only seems at present not justified, in view of the toxicity of currently available immunosuppressive regimens.
Wiik AS.Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases . Scand J Rheumatol2005; 34: 260-268 .
2.
Kallenberg CGM , Wouda AA , Hoet MH , van Venrooij WJ.Development of connective tissue disease in patients presenting with Raynaud’s phenomenon . Ann Rheum Dis1988; 47: 634-641 .
3.
Coremans IE , Spronk PE , Bootsma Het al.Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus . Am J Kidney Dis1995; 26: 595-601 .
4.
Amoura Z , Koutouzov S , Chabre Het al.Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus . Arthritis Rheum2000; 43: 76-84 .
5.
Trouw LA , Groeneveld TW , Seelen MAet al.Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes . J Clin Invest2004; 114: 679-688 .
6.
Berden JH , Licht R , van Bruggen MC , Tax WJ.Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis . Curr Opin Nephrol Hypertens1999; 8: 299-306 .
7.
Winfield JB , Faiferman I , Koffler D.Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis . J Clin Invest1977; 59: 90-96 .
8.
Roberts JL , Wyatt RJ , Schwartz MM , Lewis EJ.Differential characteristics of immune-bound antibodies in diffuse proliferative and membranous forms of lupus glomerulonephritis . Clin Immunol Immunopathol1983; 29: 223-241 .
9.
Ohnishi K , Ebling FM , Mitchell B , Singh RR , Hahn BH , Tsao BP.Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics . Int Immunol1994; 6: 817-830 .
10.
Ehrenstein MR , Katz DR , Griffiths MHet al.Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice . Kidney Int1995; 48: 705-711 .
11.
Amoura Z , Piette JC , Bach JF , Koutouzov S.The key role of nucleosomes in lupus . Arthritis Rheum1999; 42: 833-843 .
12.
Kallenberg CGM , Brouwer E , Weening JJ , Cohen Tervaert JW.Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysio-logical potential . Kidney Int1994; 46: 1-15 .
13.
Savige J , Gillis D , Benson Eet al.International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) . Am J Clin Pathol1999; 111: 507-513 .
14.
Rao JK , Weinberger M , Oddone EZ , Allen NB , Landsman P , Feussner JR.The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis . Ann Intern Med1995; 123: 925-932 .
15.
Hagen EC , Daha MR , Hermans Jet al.Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization . Kidney Int1998; 53: 743-753 .
16.
Rarok AA , Limburg PC , Kallenberg CGM . Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies . J Leuk Biol2003; 74: 3-15 .
17.
Savage CO , Harper L , Holland M.New findings in pathogenesis of anti-neutrophil cytoplasm antibody-associated vasculitis . Curr Opin Rheumatol2002; 14: 15-22 .
18.
Xiao H , Heeringa P , Hu Pet al.Antineutrophil cytoplasmic auto-antibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice . J Clin Invest2002; 110: 955-963 .
19.
Pfister H , Ollert M , Frohlich LFet al.Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo . Blood2004; 104: 1411-1418 .
20.
Bansal PJ , Tobin MC.Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement . Ann Allergy Asthma Immunol2004; 93: 398-401 .
21.
ter Borg EJ , Horst G , Hummel EJ , Limburg PC , Kallenberg CGM . Predictive value of rises in anti-double stranded DNA antibody levels for disease exacerbations in systemic lupus erythematosus: a longterm prospective study . Arthritis Rheum1990; 33: 634-643 .
22.
Bootsma H , Spronk PE , ter Borg EJet al.The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation . Ann Rheum Dis1997; 56: 661-666 .
23.
Isenberg DA , Dudeney C , Williams Wet al , Measurement of anti-DNA antibodies: a reappraisal using five different methods . Ann Rheum Dis1987; 46: 448-456 .
24.
Smeenk RJ , van den Brink HG , Brinkman K , Termaat RM , Berden JH , Swaak AJ.Anti-dsDNA: choice of assay in relation to clinical value . Rheumatol Int1991; 11: 101-107 .
25.
Westman KW , Selga D , Bygren Pet al.Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody . Kidney Int1998; 53: 1230-1236 .
26.
Csernok E , Holle J , Hellmich Bet al.Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener’s granulomatosis: first results from a multicentre study . Rheumatology2004; 43: 174-180 .
27.
Boomsma MM , Stegeman CA , van der Leij MJet al.Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study . Arthritis Rheum2000; 43: 2025-2033 .
28.
Damoiseaux JG , Slot MC , Vaessen M , Stegeman CA , Van Paassen P , Tervaert JW.Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis . J Clin Immunol2005; 25: 202-208 .
29.
Swaak AJ , Aarden LA , Statius van Eps LW , Feltkamp TE.Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus . Arthritis Rheum1979; 22: 226-235 .
30.
Swaak AJ , Groenwold J , Bronsveld W.Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus . Ann Rheum Dis1986; 45: 359-366 .
31.
Ho A , Magder LS , Barr SG , Petri M.Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus . Arthritis Rheum2001; 44: 2342-2349 .
32.
Bootsma H , Spronk PE , Derksen Ret al.Prevention of relapses in systemic lupus erythematosus . Lancet1995; 345: 1595-1599 .
33.
Bijl M , Horst G , Bootsma H , Limburg PC , Kallenberg CCM . Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk . Ann Rheum Dis2003; 62: 534-539 .
34.
Linnik MD , Hu JZ , Heilbrunn KR , Strand V , Hurley FL , Joh T;LJP 394 Investigator Consortium . Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus . Arthritis Rheum2005; 52: 1129-1137 .
35.
Cohen Tervaert JW , van der Woude FJ , Fauci ASet al.Association between active Wegener’s granulomatosis and anticytoplasmic antibodies . Arch Int Med1989; 149: 2461-2465 .
36.
Cohen Tervaert JW , Huitema MG , Hené RJet al.Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre . Lancet1990; 336: 709-711 .
37.
Egner W , Chapel HM.Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides . Clin Exp Immunol1990; 82: 244-249 .
38.
Chan TM , Frampton G , Jayne DRet al.Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies . Am J Kidney Dis1993; 22: 387-392 .
39.
Kerr GS , Fleisher TA , Hallahan CWet al.Limited prognostic value of changes in antineutrophil cytoplasmic antibody titre in patients with Wegener’s granulomatosis . Arthritis Rheum1993; 36: 365-371 .
40.
Davenport A , Lock RJ , Wallington T.Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test . Am J Nephrol1995; 15: 201-207 .
41.
Kyndt X , Reumaux D , Bridoux Fet al.Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis . Am J Med1999; 106: 527-533 .
42.
Nowack R , Grab I , Flores-Suarez LFet al.ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis . Nephrol Dial Transpl2001; 16: 1631-1637 .
43.
Stegeman CA , Cohen Tervaert JW , Sluiter WJ , Manson WL , de Jong PE , Kallenberg CGM . Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener’s Granulomatosis . Ann Intern Med1994; 120: 12-17 .
44.
Slot MC , Cohen Tervaert JW , Boomsma MM , Stegeman CA.A positive PR3-ANCA titre at switch to azathioprine therapy is associated with a disquieting relapse rate in ANCA-related vasculitis . Arthritis Rheum (Arthritis Care & Research)2004; 51: 269-273 .
45.
Sanders JS , Huitema MG , Kallenberg CG , Stegeman CA.Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment . Rheumatology2006; (Epub ahead of print).
46.
Han WK , Choi HK , Roth RMet al.Serial ANCA titres: useful tool for prevention of relapses in ANCA-associated vasculitis . Kidney Int2003; 63: 1079-1085 .
47.
De’Oliviera J , Gaskin G , Dash A , Rees AJ , Pusey CD.Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis . Am J Kidney Dis1995; 25: 380-389 .
48.
Jayne DR , Gaskin G , Pusey CD , Lockwood CM.ANCA and predicting relapse in systemic vasculitis . Q J Med1995; 88: 127-133 .
49.
Ara J , Mirapeix E , Rodrigues R , Saurina A , Darnell A.Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA . Nephrol Dial Transplant1999; 14: 1667-1672 .
50.
Gisslen K , Wieslander J , Westberg G , Herlitz H.Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis . J Intern Med2002; 251: 129-135 .
51.
Birck R , Schmitt WH , Kaelsch IA , van der Woude FJ.Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review . Am J Kidney Dis2006; 47: 15-23 .
